LOWFederal Register

Prospective Grant of an Exclusive Patent License: RXFP1 AGONISTS

Published Jul 23, 2026Source: Federal RegisterView original

Summary

This is a notice of a prospective exclusive patent license grant from NIH/NCATS to Modala Bio for RXFP1 agonist inventions. It is an intellectual property transaction, not a regulatory action affecting the sale, scheduling, or research use of peptides. RXFP1 agonists (relaxin receptor agonists) are largely small-molecule or biologic candidates in early development rather than commonly traded research peptides.

AI Analysis

Key Changes

•NIH/NCATS intends to grant an exclusive patent license for RXFP1 agonist inventions to Modala Bio, Inc.
•Exclusivity could restrict commercial development rights to these specific patented RXFP1 agonist compounds
•No change to controlled substance scheduling, sales restrictions, or research availability of peptides

Affected Compound

RXFP1 agonists (relaxin family peptide receptor 1 agonists)

Action Required

No action required for most peptide vendors/researchers. Parties with a competing interest in RXFP1 agonist IP may file objections or license applications within the comment period specified in the full Federal Register notice.

Full Document Text

The National Center for Advancing Translational Sciences, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the SUPPLEMENTARY INFORMATION section of this Notice to Modala Bio, Inc. (Modala), headquartered in Delaware.

Alert created: Jul 23, 2026, 8:01 AM